C
ClostraBio
A startup developing a drug that can prevent allergic reactions to food
About ClostraBio
ClostraBio is a pioneering company focused on developing dietary supplements and therapeutics aimed at improving gut health, treating inflammatory bowel disease (IBD), and managing food allergies. Operating in the healthcare and biotechnology market, ClostraBio serves patients and healthcare providers seeking advanced solutions for gut-related health issues. The company's core product offerings include a novel probiotic strain called CLB 101 and a plug-and-play platform for delivering bacterial metabolites. CLB 101 is an anaerobic, spore-forming, butyrate-producing probiotic that has shown promise in preventing allergic responses in preclinical studies. ClostraBio generates revenue through the sale of its dietary supplements and potential licensing of its proprietary technology to other healthcare entities. The business model is centered around continuous innovation and scientific validation to ensure the efficacy and safety of its products. By addressing unmet needs in gut health and food allergy management, ClostraBio aims to establish itself as a leader in the biotech industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Chicago, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 81.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Mar 2025 | $0 | — | Next Gen Nutrition Investment Partners · The Illinois Innovation Venture Fund | ↗ |
| EARLY VCOther financing | Oct 2022 | $11M | $44M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for ClostraBio is 3K monthly website visits, up 229.7% over the last three months. ClostraBio's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Portal Innovations
Next Gen Nutrition Investment Partners- TFThe Illinois Innovation Venture Fund
Other known investors2 additional known investors
The University of Chicago
Stone Mountain Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ClostraBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ClostraBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.